TNFRSF25 抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P00341(TNFRSF25  Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P00341(TNFRSF25  Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

TNFRSF25 (Tumor Necrosis Factor Receptor Superfamily Member 25), also known as death receptor 3 (DR3), is a cell surface receptor belonging to the TNF receptor superfamily. It is primarily expressed on activated T lymphocytes and certain innate immune cells. Its ligand, TL1A (TNF-like ligand 1A), binds to TNFRSF25. triggering signaling pathways such as NF-κB and MAPK, which regulate inflammatory responses, cell survival, and apoptosis. TNFRSF25 contains a cytoplasmic death domain that facilitates apoptosis signaling under specific conditions, though its primary role often involves modulating immune activation and tolerance.

Antibodies targeting TNFRSF25 are of interest in immunotherapy and autoimmune disease research. Agonistic anti-TNFRSF25 antibodies mimic TL1A activity, potentially enhancing T cell responses in cancer immunotherapy or autoimmune contexts. Conversely, antagonistic antibodies block TL1A binding, aiming to suppress chronic inflammation in diseases like inflammatory bowel disease (IBD), rheumatoid arthritis, or psoriasis. Studies also explore its role in regulatory T cell (Treg) expansion and tissue-specific immunity. Preclinical models suggest TNFRSF25 modulation could influence autoimmune pathogenesis or anti-tumor immunity, making it a therapeutic target under investigation. However, its dual pro-inflammatory and apoptotic roles require context-specific antibody design to optimize clinical outcomes. Current research focuses on balancing efficacy with safety in autoimmune and oncological applications.